From PCOS to PMOS: insulin resistance, obesity, and the role of GLP-1 receptor agonists in stepwise therapy
Background. In 2026, an international consensus endorsed a new name for polycystic ovary syndrome (PCOS) – "polyendocrine-metabolic ovarian syndrome" (PMOS). The new nomenclature reflects the systemic and pathogenetically heterogeneous nature of the disorder, in which abnormalities of ovulation and steroidogenesis coex...